Clinical Trials Using Anti-FGFR2 Monoclonal Antibody FPA144
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-FGFR2 Monoclonal Antibody FPA144. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric / Gastroesophageal Junction Cancer (FIGHT)
This is a global, randomized, double-blind, controlled study to evaluate the efficacy of bemarituzumab (FPA144) + mFOLFOX6 versus placebo + mFOLFOX6 in patients with FGFR2 selected Gastric Cancer (as determined by prospective IHC FGFR2b overexpression and / or a ctDNA blood assay demonstrating FGFR2 gene amplification)
Location: 5 locations